Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
35,033
archived clinical trials in
Lung Cancer

Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer
Randomized Phase II Study of Single Agent OSI-906, an Oral, Small Molecule, Tyrosine Kinase Inhibitor (TKI) of the Insulin Growth Factor-1 Receptor (IGF-1R) Versus Topotecan for the Treatment of Patients With Relapsed Small Cell Lung Cancer (SCLC)
Status: Enrolling
Updated:  12/10/2015
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer
Randomized Phase II Study of Single Agent OSI-906, an Oral, Small Molecule, Tyrosine Kinase Inhibitor (TKI) of the Insulin Growth Factor-1 Receptor (IGF-1R) Versus Topotecan for the Treatment of Patients With Relapsed Small Cell Lung Cancer (SCLC)
Status: Enrolling
Updated: 12/10/2015
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer
Randomized Phase II Study of Single Agent OSI-906, an Oral, Small Molecule, Tyrosine Kinase Inhibitor (TKI) of the Insulin Growth Factor-1 Receptor (IGF-1R) Versus Topotecan for the Treatment of Patients With Relapsed Small Cell Lung Cancer (SCLC)
Status: Enrolling
Updated:  12/10/2015
Vanderbilt University/Ingram Cancer Center
mi
from
Nashville, TN
Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer
Randomized Phase II Study of Single Agent OSI-906, an Oral, Small Molecule, Tyrosine Kinase Inhibitor (TKI) of the Insulin Growth Factor-1 Receptor (IGF-1R) Versus Topotecan for the Treatment of Patients With Relapsed Small Cell Lung Cancer (SCLC)
Status: Enrolling
Updated: 12/10/2015
Vanderbilt University/Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer
Randomized Phase II Study of Single Agent OSI-906, an Oral, Small Molecule, Tyrosine Kinase Inhibitor (TKI) of the Insulin Growth Factor-1 Receptor (IGF-1R) Versus Topotecan for the Treatment of Patients With Relapsed Small Cell Lung Cancer (SCLC)
Status: Enrolling
Updated:  12/10/2015
Johns Hopkins Singapore
mi
from
Singapore,
Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer
Randomized Phase II Study of Single Agent OSI-906, an Oral, Small Molecule, Tyrosine Kinase Inhibitor (TKI) of the Insulin Growth Factor-1 Receptor (IGF-1R) Versus Topotecan for the Treatment of Patients With Relapsed Small Cell Lung Cancer (SCLC)
Status: Enrolling
Updated: 12/10/2015
Johns Hopkins Singapore
mi
from
Singapore,
Click here to add this to my saved trials
Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers
A Phase I Safety and Tolerability Study of LBH589 in Combination With Sorafenib in Patients With Advanced Renal Cell Carcinoma, Soft Tissue Sarcoma, and Non-small Cell Lung Carcinoma (NSCLC) of Non-squamous Histologies.
Status: Enrolling
Updated:  12/11/2015
Medical University of South Carolina Hollings Cancer Center
mi
from
Charleston, SC
Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers
A Phase I Safety and Tolerability Study of LBH589 in Combination With Sorafenib in Patients With Advanced Renal Cell Carcinoma, Soft Tissue Sarcoma, and Non-small Cell Lung Carcinoma (NSCLC) of Non-squamous Histologies.
Status: Enrolling
Updated: 12/11/2015
Medical University of South Carolina Hollings Cancer Center
mi
from
Charleston, SC
Click here to add this to my saved trials
Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC)
Phase II Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/11/2015
NYU Clinical Cancer Center
mi
from
New York, NY
Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC)
Phase II Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/11/2015
NYU Clinical Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC)
Phase II Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/11/2015
NYU Langone Medical Center/Tisch Hospital
mi
from
New York, NY
Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC)
Phase II Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/11/2015
NYU Langone Medical Center/Tisch Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Gefitinib and Everolimus in Treating Patients With Stage IIIB or Stage IV or Recurrent Non-Small Cell Lung Cancer
A Phase I/II Trial of Fixed Doses of Daily Gefitinib With Escalating Doses of Daily RAD001 in Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/15/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Gefitinib and Everolimus in Treating Patients With Stage IIIB or Stage IV or Recurrent Non-Small Cell Lung Cancer
A Phase I/II Trial of Fixed Doses of Daily Gefitinib With Escalating Doses of Daily RAD001 in Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/15/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Phase I Study of Weekly Topotecan in Combination With Sorafenib in Treatment of Relapsed Small Cell Lung Cancer
Phase I Study of Weekly Topotecan in Combination With Sorafenib in Treatment of Relapsed Small Cell Lung Cancer
Status: Enrolling
Updated:  12/15/2015
Park Nicollet Institute
mi
from
St. Louis Park, MN
Phase I Study of Weekly Topotecan in Combination With Sorafenib in Treatment of Relapsed Small Cell Lung Cancer
Phase I Study of Weekly Topotecan in Combination With Sorafenib in Treatment of Relapsed Small Cell Lung Cancer
Status: Enrolling
Updated: 12/15/2015
Park Nicollet Institute
mi
from
St. Louis Park, MN
Click here to add this to my saved trials
Ph II OSI-774 (Erlotinib,Tarceva) In Advanced Bronchioloalveolar Cell Lung Cancer
Multicenter Phase II Trial of OSI-774 (Erlotinib, Tarceva) In Patients With Advanced Bronchioloalveolar Cell Lung Cancer
Status: Enrolling
Updated:  12/15/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Ph II OSI-774 (Erlotinib,Tarceva) In Advanced Bronchioloalveolar Cell Lung Cancer
Multicenter Phase II Trial of OSI-774 (Erlotinib, Tarceva) In Patients With Advanced Bronchioloalveolar Cell Lung Cancer
Status: Enrolling
Updated: 12/15/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations
A Multicenter, Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations Who Have Progressed on Prior EGFR TKI Treatment
Status: Enrolling
Updated:  12/16/2015
Cedars Sinai Medical Center Dept.of Cedars-Sinai Med. Ctr.
mi
from
Los Angeles, CA
An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations
A Multicenter, Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations Who Have Progressed on Prior EGFR TKI Treatment
Status: Enrolling
Updated: 12/16/2015
Cedars Sinai Medical Center Dept.of Cedars-Sinai Med. Ctr.
mi
from
Los Angeles, CA
Click here to add this to my saved trials
An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations
A Multicenter, Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations Who Have Progressed on Prior EGFR TKI Treatment
Status: Enrolling
Updated:  12/16/2015
University of Wisconsin / Paul P. Carbone Comp Cancer Center Univ Wisc 5
mi
from
Madison, WI
An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations
A Multicenter, Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations Who Have Progressed on Prior EGFR TKI Treatment
Status: Enrolling
Updated: 12/16/2015
University of Wisconsin / Paul P. Carbone Comp Cancer Center Univ Wisc 5
mi
from
Madison, WI
Click here to add this to my saved trials
An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations
A Multicenter, Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations Who Have Progressed on Prior EGFR TKI Treatment
Status: Enrolling
Updated:  12/16/2015
Maryland Oncology Hematology, P.A. SC
mi
from
Rockville, MD
An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations
A Multicenter, Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations Who Have Progressed on Prior EGFR TKI Treatment
Status: Enrolling
Updated: 12/16/2015
Maryland Oncology Hematology, P.A. SC
mi
from
Rockville, MD
Click here to add this to my saved trials
An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations
A Multicenter, Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations Who Have Progressed on Prior EGFR TKI Treatment
Status: Enrolling
Updated:  12/16/2015
Novartis Investigative Site
mi
from
Creteil,
An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations
A Multicenter, Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations Who Have Progressed on Prior EGFR TKI Treatment
Status: Enrolling
Updated: 12/16/2015
Novartis Investigative Site
mi
from
Creteil,
Click here to add this to my saved trials
Dasatinib in Treating Patients With Advanced Lung Cancer That Is No Longer Responding to Erlotinib or Gefitinib
A Phase 2 Trial of Dasatinib in Patients With Lung Adenocarcinoma With Acquired Resistance to Erlotinib or Gefitinib
Status: Enrolling
Updated:  12/16/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Dasatinib in Treating Patients With Advanced Lung Cancer That Is No Longer Responding to Erlotinib or Gefitinib
A Phase 2 Trial of Dasatinib in Patients With Lung Adenocarcinoma With Acquired Resistance to Erlotinib or Gefitinib
Status: Enrolling
Updated: 12/16/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Phase II Trial to Correlate Radiographic Response Induced By Gefitinib With Mutations in the Protein-Tyrosine Kinase Domain of the EGF Receptor Gene
Phase II Trial to Correlate Radiographic Response Induced By Gefitinib With Mutations in the Protein-Tyrosine Kinase Domain of the EGF Receptor Gene in Patients With NSCLC
Status: Enrolling
Updated:  12/17/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Phase II Trial to Correlate Radiographic Response Induced By Gefitinib With Mutations in the Protein-Tyrosine Kinase Domain of the EGF Receptor Gene
Phase II Trial to Correlate Radiographic Response Induced By Gefitinib With Mutations in the Protein-Tyrosine Kinase Domain of the EGF Receptor Gene in Patients With NSCLC
Status: Enrolling
Updated: 12/17/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Multimodality Treatment for Patients With Resectable Non-Small Cell Lung Cancer (NSCLC) - BEACON Study: Bevacizumab and Chemotherapy for Operable NSCLC
Multimodality Treatment for Patients With Resectable Non-Small Cell Lung Cancer (NSCLC) (BEACON Study: Bevacizumab and Chemotherapy for Operable NSCLC)
Status: Enrolling
Updated:  12/18/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Multimodality Treatment for Patients With Resectable Non-Small Cell Lung Cancer (NSCLC) - BEACON Study: Bevacizumab and Chemotherapy for Operable NSCLC
Multimodality Treatment for Patients With Resectable Non-Small Cell Lung Cancer (NSCLC) (BEACON Study: Bevacizumab and Chemotherapy for Operable NSCLC)
Status: Enrolling
Updated: 12/18/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer
A First-in-man Phase I/II Single-agent Open-label Dose-escalation Study of Every Three-week Dosing of Oral ONC201 in Patients With Advanced Cancer and Limited Treatment Options
Status: Enrolling
Updated:  12/18/2015
Massachusetts General Hospital
mi
from
Boston, MA
A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer
A First-in-man Phase I/II Single-agent Open-label Dose-escalation Study of Every Three-week Dosing of Oral ONC201 in Patients With Advanced Cancer and Limited Treatment Options
Status: Enrolling
Updated: 12/18/2015
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of Intermittent, High-dose Afatinib to Determine the Maximal Tolerated Dose and Assess Activity of This Dose Against Non-small Cell Lung Cancer With T790M Mutations
A Phase 1b Study of Intermittent Administration of High Doses of the Irreversible EGFR Inhibitor Afatinib as a Means of Achieving Plasma Levels Active Against Non-small Cell Lung Cancer With Known T790M Mutations
Status: Enrolling
Updated:  12/21/2015
1199.14.1190 Boehringer Ingelheim Investigational Site
mi
from
Aurora, CO
A Study of Intermittent, High-dose Afatinib to Determine the Maximal Tolerated Dose and Assess Activity of This Dose Against Non-small Cell Lung Cancer With T790M Mutations
A Phase 1b Study of Intermittent Administration of High Doses of the Irreversible EGFR Inhibitor Afatinib as a Means of Achieving Plasma Levels Active Against Non-small Cell Lung Cancer With Known T790M Mutations
Status: Enrolling
Updated: 12/21/2015
1199.14.1190 Boehringer Ingelheim Investigational Site
mi
from
Aurora, CO
Click here to add this to my saved trials
A Study of Intermittent, High-dose Afatinib to Determine the Maximal Tolerated Dose and Assess Activity of This Dose Against Non-small Cell Lung Cancer With T790M Mutations
A Phase 1b Study of Intermittent Administration of High Doses of the Irreversible EGFR Inhibitor Afatinib as a Means of Achieving Plasma Levels Active Against Non-small Cell Lung Cancer With Known T790M Mutations
Status: Enrolling
Updated:  12/21/2015
205.440.1003 Boehringer Ingelheim Investigational Site
mi
from
Boston, MA
A Study of Intermittent, High-dose Afatinib to Determine the Maximal Tolerated Dose and Assess Activity of This Dose Against Non-small Cell Lung Cancer With T790M Mutations
A Phase 1b Study of Intermittent Administration of High Doses of the Irreversible EGFR Inhibitor Afatinib as a Means of Achieving Plasma Levels Active Against Non-small Cell Lung Cancer With Known T790M Mutations
Status: Enrolling
Updated: 12/21/2015
205.440.1003 Boehringer Ingelheim Investigational Site
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of Intermittent, High-dose Afatinib to Determine the Maximal Tolerated Dose and Assess Activity of This Dose Against Non-small Cell Lung Cancer With T790M Mutations
A Phase 1b Study of Intermittent Administration of High Doses of the Irreversible EGFR Inhibitor Afatinib as a Means of Achieving Plasma Levels Active Against Non-small Cell Lung Cancer With Known T790M Mutations
Status: Enrolling
Updated:  12/21/2015
205.440.1003 Boehringer Ingelheim Investigational Site
mi
from
Boston, MA
A Study of Intermittent, High-dose Afatinib to Determine the Maximal Tolerated Dose and Assess Activity of This Dose Against Non-small Cell Lung Cancer With T790M Mutations
A Phase 1b Study of Intermittent Administration of High Doses of the Irreversible EGFR Inhibitor Afatinib as a Means of Achieving Plasma Levels Active Against Non-small Cell Lung Cancer With Known T790M Mutations
Status: Enrolling
Updated: 12/21/2015
205.440.1003 Boehringer Ingelheim Investigational Site
mi
from
Boston, MA
Click here to add this to my saved trials
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
A Phase 2 Study of ARQ 197 in Patients With Previously-Treated Malignant Mesothelioma
Status: Enrolling
Updated:  12/21/2015
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
A Phase 2 Study of ARQ 197 in Patients With Previously-Treated Malignant Mesothelioma
Status: Enrolling
Updated: 12/21/2015
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
A Phase 2 Study of ARQ 197 in Patients With Previously-Treated Malignant Mesothelioma
Status: Enrolling
Updated:  12/21/2015
City of Hope South Pasadena
mi
from
South Pasadena, CA
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
A Phase 2 Study of ARQ 197 in Patients With Previously-Treated Malignant Mesothelioma
Status: Enrolling
Updated: 12/21/2015
City of Hope South Pasadena
mi
from
South Pasadena, CA
Click here to add this to my saved trials
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
A Phase 2 Study of ARQ 197 in Patients With Previously-Treated Malignant Mesothelioma
Status: Enrolling
Updated:  12/21/2015
Decatur Memorial Hospital
mi
from
Decatur, IL
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
A Phase 2 Study of ARQ 197 in Patients With Previously-Treated Malignant Mesothelioma
Status: Enrolling
Updated: 12/21/2015
Decatur Memorial Hospital
mi
from
Decatur, IL
Click here to add this to my saved trials
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
A Phase 2 Study of ARQ 197 in Patients With Previously-Treated Malignant Mesothelioma
Status: Enrolling
Updated:  12/21/2015
NorthShore University HealthSystem-Evanston Hospital
mi
from
Evanston, IL
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
A Phase 2 Study of ARQ 197 in Patients With Previously-Treated Malignant Mesothelioma
Status: Enrolling
Updated: 12/21/2015
NorthShore University HealthSystem-Evanston Hospital
mi
from
Evanston, IL
Click here to add this to my saved trials
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
A Phase 2 Study of ARQ 197 in Patients With Previously-Treated Malignant Mesothelioma
Status: Enrolling
Updated:  12/21/2015
Ingalls Memorial Hospital
mi
from
Harvey, IL
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
A Phase 2 Study of ARQ 197 in Patients With Previously-Treated Malignant Mesothelioma
Status: Enrolling
Updated: 12/21/2015
Ingalls Memorial Hospital
mi
from
Harvey, IL
Click here to add this to my saved trials
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
A Phase 2 Study of ARQ 197 in Patients With Previously-Treated Malignant Mesothelioma
Status: Enrolling
Updated:  12/21/2015
Illinois CancerCare-Peoria
mi
from
Peoria, IL
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
A Phase 2 Study of ARQ 197 in Patients With Previously-Treated Malignant Mesothelioma
Status: Enrolling
Updated: 12/21/2015
Illinois CancerCare-Peoria
mi
from
Peoria, IL
Click here to add this to my saved trials
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
A Phase 2 Study of ARQ 197 in Patients With Previously-Treated Malignant Mesothelioma
Status: Enrolling
Updated:  12/21/2015
Fort Wayne Medical Oncology and Hematology Inc-Parkview
mi
from
Fort Wayne, IN
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
A Phase 2 Study of ARQ 197 in Patients With Previously-Treated Malignant Mesothelioma
Status: Enrolling
Updated: 12/21/2015
Fort Wayne Medical Oncology and Hematology Inc-Parkview
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
A Phase 2 Study of ARQ 197 in Patients With Previously-Treated Malignant Mesothelioma
Status: Enrolling
Updated:  12/21/2015
Wayne State University/Karmanos Cancer Institute
mi
from
Detroit, MI
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
A Phase 2 Study of ARQ 197 in Patients With Previously-Treated Malignant Mesothelioma
Status: Enrolling
Updated: 12/21/2015
Wayne State University/Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
A Phase 2 Study of ARQ 197 in Patients With Previously-Treated Malignant Mesothelioma
Status: Enrolling
Updated:  12/21/2015
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
A Phase 2 Study of ARQ 197 in Patients With Previously-Treated Malignant Mesothelioma
Status: Enrolling
Updated: 12/21/2015
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
A Phase 2 Study of ARQ 197 in Patients With Previously-Treated Malignant Mesothelioma
Status: Enrolling
Updated:  12/21/2015
University of Pittsburgh Cancer Institute
mi
from
Pittsburgh, PA
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
A Phase 2 Study of ARQ 197 in Patients With Previously-Treated Malignant Mesothelioma
Status: Enrolling
Updated: 12/21/2015
University of Pittsburgh Cancer Institute
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
A Phase 2 Study of ARQ 197 in Patients With Previously-Treated Malignant Mesothelioma
Status: Enrolling
Updated:  12/21/2015
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
A Phase 2 Study of ARQ 197 in Patients With Previously-Treated Malignant Mesothelioma
Status: Enrolling
Updated: 12/21/2015
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
A Phase 2 Study of ARQ 197 in Patients With Previously-Treated Malignant Mesothelioma
Status: Enrolling
Updated:  12/21/2015
University of California-Davis Comprehensive Cancer Ctr
mi
from
Sacramento, CA
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
A Phase 2 Study of ARQ 197 in Patients With Previously-Treated Malignant Mesothelioma
Status: Enrolling
Updated: 12/21/2015
University of California-Davis Comprehensive Cancer Ctr
mi
from
Sacramento, CA
Click here to add this to my saved trials
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
A Phase 2 Study of ARQ 197 in Patients With Previously-Treated Malignant Mesothelioma
Status: Enrolling
Updated:  12/21/2015
Northwestern University
mi
from
Chicago, IL
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
A Phase 2 Study of ARQ 197 in Patients With Previously-Treated Malignant Mesothelioma
Status: Enrolling
Updated: 12/21/2015
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
A Phase 2 Study of ARQ 197 in Patients With Previously-Treated Malignant Mesothelioma
Status: Enrolling
Updated:  12/21/2015
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
A Phase 2 Study of ARQ 197 in Patients With Previously-Treated Malignant Mesothelioma
Status: Enrolling
Updated: 12/21/2015
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
A Phase 2 Study of ARQ 197 in Patients With Previously-Treated Malignant Mesothelioma
Status: Enrolling
Updated:  12/21/2015
Southern Illinois University School of Medicine
mi
from
Springfield, IL
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
A Phase 2 Study of ARQ 197 in Patients With Previously-Treated Malignant Mesothelioma
Status: Enrolling
Updated: 12/21/2015
Southern Illinois University School of Medicine
mi
from
Springfield, IL
Click here to add this to my saved trials
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
A Phase 2 Study of ARQ 197 in Patients With Previously-Treated Malignant Mesothelioma
Status: Enrolling
Updated:  12/21/2015
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
A Phase 2 Study of ARQ 197 in Patients With Previously-Treated Malignant Mesothelioma
Status: Enrolling
Updated: 12/21/2015
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
A Phase 2 Study of ARQ 197 in Patients With Previously-Treated Malignant Mesothelioma
Status: Enrolling
Updated:  12/21/2015
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
A Phase 2 Study of ARQ 197 in Patients With Previously-Treated Malignant Mesothelioma
Status: Enrolling
Updated: 12/21/2015
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
A Phase 2 Study of ARQ 197 in Patients With Previously-Treated Malignant Mesothelioma
Status: Enrolling
Updated:  12/21/2015
Mercy Hospital Saint Louis
mi
from
Saint Louis, MO
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
A Phase 2 Study of ARQ 197 in Patients With Previously-Treated Malignant Mesothelioma
Status: Enrolling
Updated: 12/21/2015
Mercy Hospital Saint Louis
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Amrubicin + Cyclophosphamide in Advanced Solid Organ Malignancies
A Phase I Study of Amrubicin and Cyclophosphamide in Patients With Advanced Solid Organ Malignancies
Status: Enrolling
Updated:  12/21/2015
Highlands Oncology Group
mi
from
Springdale, AR
Amrubicin + Cyclophosphamide in Advanced Solid Organ Malignancies
A Phase I Study of Amrubicin and Cyclophosphamide in Patients With Advanced Solid Organ Malignancies
Status: Enrolling
Updated: 12/21/2015
Highlands Oncology Group
mi
from
Springdale, AR
Click here to add this to my saved trials
Amrubicin + Cyclophosphamide in Advanced Solid Organ Malignancies
A Phase I Study of Amrubicin and Cyclophosphamide in Patients With Advanced Solid Organ Malignancies
Status: Enrolling
Updated:  12/21/2015
Helen F. Graham Cancer Center
mi
from
Newark, DE
Amrubicin + Cyclophosphamide in Advanced Solid Organ Malignancies
A Phase I Study of Amrubicin and Cyclophosphamide in Patients With Advanced Solid Organ Malignancies
Status: Enrolling
Updated: 12/21/2015
Helen F. Graham Cancer Center
mi
from
Newark, DE
Click here to add this to my saved trials
Amrubicin + Cyclophosphamide in Advanced Solid Organ Malignancies
A Phase I Study of Amrubicin and Cyclophosphamide in Patients With Advanced Solid Organ Malignancies
Status: Enrolling
Updated:  12/21/2015
Medical and Surgical Specialists, LLC
mi
from
Galesburg, IL
Amrubicin + Cyclophosphamide in Advanced Solid Organ Malignancies
A Phase I Study of Amrubicin and Cyclophosphamide in Patients With Advanced Solid Organ Malignancies
Status: Enrolling
Updated: 12/21/2015
Medical and Surgical Specialists, LLC
mi
from
Galesburg, IL
Click here to add this to my saved trials
Amrubicin + Cyclophosphamide in Advanced Solid Organ Malignancies
A Phase I Study of Amrubicin and Cyclophosphamide in Patients With Advanced Solid Organ Malignancies
Status: Enrolling
Updated:  12/21/2015
Cancer Care Center of Southern Indiana
mi
from
Bloomington, IN
Amrubicin + Cyclophosphamide in Advanced Solid Organ Malignancies
A Phase I Study of Amrubicin and Cyclophosphamide in Patients With Advanced Solid Organ Malignancies
Status: Enrolling
Updated: 12/21/2015
Cancer Care Center of Southern Indiana
mi
from
Bloomington, IN
Click here to add this to my saved trials
Amrubicin + Cyclophosphamide in Advanced Solid Organ Malignancies
A Phase I Study of Amrubicin and Cyclophosphamide in Patients With Advanced Solid Organ Malignancies
Status: Enrolling
Updated:  12/21/2015
Indiana University Simon Cancer Center
mi
from
Indianapolis, IN
Amrubicin + Cyclophosphamide in Advanced Solid Organ Malignancies
A Phase I Study of Amrubicin and Cyclophosphamide in Patients With Advanced Solid Organ Malignancies
Status: Enrolling
Updated: 12/21/2015
Indiana University Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Amrubicin + Cyclophosphamide in Advanced Solid Organ Malignancies
A Phase I Study of Amrubicin and Cyclophosphamide in Patients With Advanced Solid Organ Malignancies
Status: Enrolling
Updated:  12/21/2015
Medical Consultants, P.C.
mi
from
Muncie, IN
Amrubicin + Cyclophosphamide in Advanced Solid Organ Malignancies
A Phase I Study of Amrubicin and Cyclophosphamide in Patients With Advanced Solid Organ Malignancies
Status: Enrolling
Updated: 12/21/2015
Medical Consultants, P.C.
mi
from
Muncie, IN
Click here to add this to my saved trials
Amrubicin + Cyclophosphamide in Advanced Solid Organ Malignancies
A Phase I Study of Amrubicin and Cyclophosphamide in Patients With Advanced Solid Organ Malignancies
Status: Enrolling
Updated:  12/21/2015
Northern Indiana Cancer Research Consortium
mi
from
South Bend, IN
Amrubicin + Cyclophosphamide in Advanced Solid Organ Malignancies
A Phase I Study of Amrubicin and Cyclophosphamide in Patients With Advanced Solid Organ Malignancies
Status: Enrolling
Updated: 12/21/2015
Northern Indiana Cancer Research Consortium
mi
from
South Bend, IN
Click here to add this to my saved trials
Amrubicin + Cyclophosphamide in Advanced Solid Organ Malignancies
A Phase I Study of Amrubicin and Cyclophosphamide in Patients With Advanced Solid Organ Malignancies
Status: Enrolling
Updated:  12/21/2015
Siteman Cancer Center
mi
from
St. Louis, MO
Amrubicin + Cyclophosphamide in Advanced Solid Organ Malignancies
A Phase I Study of Amrubicin and Cyclophosphamide in Patients With Advanced Solid Organ Malignancies
Status: Enrolling
Updated: 12/21/2015
Siteman Cancer Center
mi
from
St. Louis, MO
Click here to add this to my saved trials
Amrubicin + Cyclophosphamide in Advanced Solid Organ Malignancies
A Phase I Study of Amrubicin and Cyclophosphamide in Patients With Advanced Solid Organ Malignancies
Status: Enrolling
Updated:  12/21/2015
Providence Portland Medical Center
mi
from
Portland, OR
Amrubicin + Cyclophosphamide in Advanced Solid Organ Malignancies
A Phase I Study of Amrubicin and Cyclophosphamide in Patients With Advanced Solid Organ Malignancies
Status: Enrolling
Updated: 12/21/2015
Providence Portland Medical Center
mi
from
Portland, OR
Click here to add this to my saved trials
Amrubicin + Cyclophosphamide in Advanced Solid Organ Malignancies
A Phase I Study of Amrubicin and Cyclophosphamide in Patients With Advanced Solid Organ Malignancies
Status: Enrolling
Updated:  12/21/2015
Fox Chase Cancer Center Extramural Research Program
mi
from
Rockledge, PA
Amrubicin + Cyclophosphamide in Advanced Solid Organ Malignancies
A Phase I Study of Amrubicin and Cyclophosphamide in Patients With Advanced Solid Organ Malignancies
Status: Enrolling
Updated: 12/21/2015
Fox Chase Cancer Center Extramural Research Program
mi
from
Rockledge, PA
Click here to add this to my saved trials
Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy in Non-small Cell Lung Cancer (NSCLC)
A Randomized Phase II Study of Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy for Advance Non-small Cell Lung Cancer(NSCLC)
Status: Enrolling
Updated:  12/22/2015
Achieve Clinical Research
mi
from
Birmingham, AL
Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy in Non-small Cell Lung Cancer (NSCLC)
A Randomized Phase II Study of Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy for Advance Non-small Cell Lung Cancer(NSCLC)
Status: Enrolling
Updated: 12/22/2015
Achieve Clinical Research
mi
from
Birmingham, AL
Click here to add this to my saved trials
Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy in Non-small Cell Lung Cancer (NSCLC)
A Randomized Phase II Study of Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy for Advance Non-small Cell Lung Cancer(NSCLC)
Status: Enrolling
Updated:  12/22/2015
Clearview Cancer Institute
mi
from
Huntsville, AL
Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy in Non-small Cell Lung Cancer (NSCLC)
A Randomized Phase II Study of Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy for Advance Non-small Cell Lung Cancer(NSCLC)
Status: Enrolling
Updated: 12/22/2015
Clearview Cancer Institute
mi
from
Huntsville, AL
Click here to add this to my saved trials